AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 7973107
Drug: Nebulised salbutamol
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nebulised salbutamol (5 mg) given 4 times daily for 24 hours on 2 consecutive days
Trial: 7973107
Drug: Saline given
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline given 4 times daily for 24 hours on 2 consecutive days
Trial: 2659302
Drug: Sucrose-containing snacks
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sucrose-containing snacks (7% of total daily calories)
Trial: 2659302
Drug: Aspartame-sweetened snacks
RxNorm normalized name: Aspartame
DrugBank: Aspartame (DB00168)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspartame-sweetened snacks (1% of total daily calories)
Trial: 30980248
Drug: Non-daily smokers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-daily smokers
Trial: 29354957
Drug: Fire needle
RxNorm normalized name: Fire Out
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fire needle plus chemotherapy
Trial: 18271771
Drug: Topical therapy
RxNorm normalized name: Diclosaicin 1.5%-0.025% Topical Therapy Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical therapy with 0.2% minocycline
Trial: 18271771
Drug: Placebo aqueous
RxNorm normalized name: Pen-Aqueous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo aqueous solution mouthwash
Trial: 12430110
Drug: Single stimulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single stimulation group (30 mL local anesthetic injected after locating 1 motor response)
Trial: 12430110
Drug: Multistimulation group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multistimulation group (10 mL local anesthetic injected on each of 3 motor responses)
Trial: 10087113
Drug: Intravenous injection
RxNorm normalized name: Meta Trace FDG, intravenous injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injection of mangafodipir trisodium (Mn‐DPDP) at a dosage of 5 micromol/kg.
Trial: 7552592
Drug: Enteral allopurinol
RxNorm normalized name: Allopurinol
DrugBank: Allopurinol (DB00437)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Enteral allopurinol (20 mg/ml) for seven daily doses
Trial: 7552592
Drug: Placebo (equivalent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (equivalent dose) for seven daily doses
Trial: 7552592
Drug: Enteral allopurinol
RxNorm normalized name: Allopurinol
DrugBank: Allopurinol (DB00437)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Enteral allopurinol (20 mg/ml)
Trial: 2210808
Drug: Sodium citrate
RxNorm normalized name: Sodium Citrate
DrugBank: Sodium nitrate (DB15952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium citrate (200 mmol sodium/day) as a supplement to the low salt diet for a third week
Trial: 6933738
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg cyproterone acetate at weekly intervals
Trial: 6933738
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg oestradiol‐17 beta‐undecylate every month
Trial: 6151553
Drug: Prizidilol hydrochloride
RxNorm normalized name: Chlorpromazine Hydrochloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prizidilol hydrochloride (200‐300 mg b.i.d.)
Trial: 31348732
Drug: Language-specific attention
RxNorm normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Language-specific attention treatment (L-SAT)
Trial: 26814620
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin type A (BTX‐A) 200U subcutaneous injection
Trial: 22790464
Drug: Hepatitis C
RxNorm normalized name: hepatitis C virus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatitis C antiviral therapy offered to patients in opioid agonist treatment
Trial: 20962312
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil beverage (1.5 g per day for 12 weeks)
Trial: 16225928
Drug: Early retreatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early retreatment with verteporfin therapy every 2 months (group A)
Trial: 16225928
Drug: Standard verteporfin
RxNorm normalized name: Verteporfin
DrugBank: Verteporfin (DB00460)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Standard verteporfin therapy every 3 months (group B)
Trial: 16225928
Drug: Early retreatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early retreatment with verteporfin therapy (group A)
Trial: 16225928
Drug: Standard verteporfin
RxNorm normalized name: Verteporfin
DrugBank: Verteporfin (DB00460)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Standard verteporfin therapy (group B)
Trial: 29561188
Drug: Sitagliptin-Metformin (SITA-MET)
RxNorm normalized name: linagliptin / metformin
DrugBank: Sitagliptin (DB01261)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sitagliptin-Metformin (SITA-MET)
Trial: 27218868
Drug: Mirtazapine (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirtazapine (15 mg/d for 1 week and then 30 mg/d for 12 weeks)
Trial: 15058375
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment alone (control group)
Trial: 10640160
Drug: Norplant implant
RxNorm normalized name: Norplant 3-oxime
DrugBank: Norelgestromin (DB06713)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Norplant implant
Trial: 10640160
Drug: Domestic implant
RxNorm normalized name: domestic cow dander extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Domestic implant
Trial: 7589771
Drug: Alpha-glucosidase inhibitor
RxNorm normalized name: Alpha-glucosidase inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpha-glucosidase inhibitor (0.6 mg/day) combined with sulphonylurea (glibenclamide or tolbutamide) for 4 weeks
Trial: 7015536
Drug: Fixed-dose combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose combination of penbutolol (40 mg) and furosemide (20 mg)
Trial: 7015536
Drug: Reference formulations:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulations: Penbutolol capsules (40 mg) and furosemide (20 mg) tablets
Trial: 11929440
Drug: Group therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group therapy programme for adult survivors of child abuse and neglect
Trial: 9617508
Drug: Ropinirole (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropinirole (mean daily dose 8.7 mg in early therapy; 8.2 mg in adjunct therapy)
Trial: 2656070
Drug: Prostacyclin (PGI2)
RxNorm normalized name: PGI2
DrugBank: Epoprostenol (DB01240)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prostacyclin (PGI2) during ANG II infusion
Trial: 8848911
Drug: Balanced analgesia
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Balanced analgesia (5 ml of 2% lidocaine gel on the clips and 200 mg of ketoprofen i.v.)
Trial: 8848911
Drug: Placebo (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (5 ml of placebo gel on the clips and placebo i.v.)
Trial: 8848911
Drug: Lidocaine group
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine group (5 ml of 2% lidocaine gel on the clips and placebo i.v.)
Trial: 8504578
Drug: Intravenous magnesium
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous magnesium sulfate (bolus doses of 5 + 5 mmol followed by infusion of 0.04 mmol/min)
Trial: 8504578
Drug: Verapamil (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil (5 + 5 mg followed by 0.1 mg/min)
Trial: 23234601
Drug: pegIFNα‐2a continuing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pegIFNα‐2a continuing monotherapy (group A, n = 51)
Trial: 23234601
Drug: Adefovir (ADV)
DrugBank: Adefovir (DB13868)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adefovir (ADV) add‐on therapy (group B, n = 34)
Trial: 15261701
Drug: D2 receptor
RxNorm normalized name: vitamin D2
DrugBank: Ergocalciferol (DB00153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: D2 receptor agonist bromocriptine 3.125 mg
Trial: 10680473
Drug: r-HuEPO (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: r-HuEPO (300 IU/kg on day four before surgery and 150 IU/kg daily for the following seven days)
Trial: 8975318
Drug: Resting 99mTc-MIBI
RxNorm normalized name: Rest Simply
DrugBank: Diphenhydramine (DB01075)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Resting 99mTc-MIBI SPECT after nitroglycerine (NTG) administration
Trial: 1757606
Drug: 0.05% betamethasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05% betamethasone dipropionate ointment
Trial: 28819778
Drug: Jumihaidokuto (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Jumihaidokuto (6 g daily)
Trial: 28819778
Drug: Control (antihistamines
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (antihistamines only)
Trial: 25833401
Drug: Subcutaneous PEG‐IFN‐β1a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous PEG‐IFN‐β1a
Trial: 25833401
Drug: Conventional IFN‐β
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional IFN‐β drugs
Trial: 17127381
Drug: Transdermal buprenorphine
RxNorm normalized name: buprenorphine Transdermal System
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Transdermal buprenorphine (35 microg/h)
Trial: 17127381
Drug: Sustained-release morphine
RxNorm normalized name: morphine Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release morphine (60 mg/day)
Trial: 9385692
Drug: Routine epidural
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine epidural corticosteroid injections
Trial: 9385692
Drug: Rest and
RxNorm normalized name: Rest Simply
DrugBank: Diphenhydramine (DB01075)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rest and a nonsteroidal antiinflammatory drug
Trial: 4934047
Drug: Levorphanol 2
RxNorm normalized name: levorphanol 2 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levorphanol 2 mg
Trial: 4934047
Drug: Pentazocine 20
RxNorm normalized name: Pentazocine
DrugBank: Pentazocine (DB00652)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pentazocine 20 mg
Trial: 4934047
Drug: Morphine 10
RxNorm normalized name: morphine 10 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine 10 mg and Cyclizine 50 mg combination
Trial: 31519277
Drug: Dengzhan Shengmai
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dengzhan Shengmai (DZSM) capsules, 0.36 g, twice daily for 12 months
Trial: 28650791
Drug: Papain gel
RxNorm normalized name: Papain
DrugBank: Papain (DB11193)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Papain gel after acid etching for 60 seconds
Trial: 28650791
Drug: Bromelain gel
DrugBank: Bromelains (DB13281)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromelain gel after acid etching for 60 seconds
Trial: 24621936
Drug: Standard CHF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard CHF therapy (Control)
Trial: 21644059
Drug: MK‐3134 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK‐3134 25 mg
Trial: 21644059
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of MK‐3134 and Donepezil
Trial: 18552277
Drug: Istradefylline (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Istradefylline (40 mg daily for 14 days)
Trial: 18552277
Drug: Atorvastatin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin (40 mg single dose)
Trial: 11139103
Drug: Fentanyl (8.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl (8.1 ng/mL)
Trial: 11139103
Drug: Sufentanil (0.68
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufentanil (0.68 ng/mL)
Trial: 8472829
Drug: 0.8 mg
RxNorm normalized name: biotin 0.8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.8 mg budesonide
Trial: 30153096
Drug: Hydroxycarbamide plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxycarbamide plus aspirin
Trial: 24704290
Drug: 20 ml
RxNorm normalized name: Exact-Med, 20 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 ml aspiration
Trial: 24704290
Drug: 10 ml
RxNorm normalized name: Vial Empty 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 ml aspiration
Trial: 24704290
Drug: 0 ml
RxNorm normalized name: TPN Bag 250 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 ml aspiration (no aspiration)
Trial: 16036198
Drug: Step-up ovulation
RxNorm normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Step-up ovulation induction treatment with recombinant follicle-stimulating hormone followed by intrauterine insemination for three cycles
Trial: 9926183
Drug: Metoclopramide 10
RxNorm normalized name: metoclopramide 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide 10 mg i.v. before propofol (2 mg/kg) induction (Group A)
Trial: 9926183
Drug: Lidocaine 40
RxNorm normalized name: lidocaine 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine 40 mg (Group D)
Trial: 340332
Drug: Cimetidine plus
RxNorm normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cimetidine plus antacid
Trial: 340332
Drug: Cimetidine plus
RxNorm normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cimetidine plus dummy antacid
Trial: 340332
Drug: Placebo tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet plus antacid
Trial: 25461822
Drug: Motor Learning
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Motor Learning (ML) alone
Trial: 25461822
Drug: Robotics plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Robotics plus Motor Learning (ML)
Trial: 25461822
Drug: Functional Electrical
RxNorm normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Functional Electrical Stimulation (FES) plus Motor Learning (ML)
Trial: 23365053
Drug: Intranasal ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal ketamine 25 mg
Trial: 23365053
Drug: Intranasal midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intranasal midazolam 2 mg
Trial: 19584603
Drug: Physical Activity
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical Activity (PA) during treatment
Trial: 15034827
Drug: New cell-cultured
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New cell-cultured smallpox vaccine
Trial: 15034827
Drug: Live vaccinia
RxNorm normalized name: Smallpox (Vaccinia) Vaccine, Live
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live vaccinia virus vaccine
Trial: 11685164
Drug: Unfractionated heparin
RxNorm normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unfractionated heparin 70 U/kg
Trial: 11685164
Drug: Both unfractionated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both unfractionated heparin and dalteparin
Trial: 9922821
Drug: Customary treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Customary treatment
Trial: 7998416
Drug: B subunit-whole
RxNorm normalized name: covid-19, protein subunit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B subunit-whole cell cholera vaccine (B-WC), 2 or 3 doses
Trial: 7998416
Drug: B subunit-whole
RxNorm normalized name: covid-19, protein subunit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B subunit-whole cell cholera vaccine (B-WC), 2 doses
Trial: 7998416
Drug: New B
RxNorm normalized name: Little Remedies New Baby Essentials Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New B subunit-whole cell cholera vaccine (recombinant B subunit)
Trial: 1947729
Drug: High-dose corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose corticosteroids (HDC)
Trial: 25609264
Drug: n-3 PUFAs
RxNorm normalized name: 22:6(n-3)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n-3 PUFAs enriched intravenous fat emulsion (IVFE)
Trial: 23875551
Drug: Cognitive behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioral group therapy (4 sessions)
Trial: 18379396
Drug: Vardenafil 10
RxNorm normalized name: vardenafil 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vardenafil 10 mg for 4 weeks, then maintained or titrated to 5 or 20 mg at weeks 4 and 8
Trial: 10574413
Drug: Irbesartan monotherapy
RxNorm normalized name: Irbesartan
DrugBank: Irbesartan (DB01029)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Irbesartan monotherapy started at 75 mg and titrated to 300 mg
Trial: 8921578
Drug: Terlipressin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terlipressin (2 mg initially, 1 mg every four hours for 24 hours)
Trial: 8921578
Drug: Somatostatin (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Somatostatin (250 micrograms bolus and continuous infusion of 250 micrograms/h for 24 hours)
Trial: 2060544
Drug: Amitriptyline (37.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitriptyline (37.5 mg)
Trial: 30166329
Drug: eBEACOPP (escalated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: eBEACOPP (escalated doses of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone)
Trial: 18046975
Drug: Zofenopril 30-60
RxNorm normalized name: zofenopril 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zofenopril 30-60 mg once daily
Trial: 11094308
Drug: Interferon (IFN)
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon (IFN) alpha‐2b at a dose of 20 MU/m2/day, 5 days per week for one month, followed by 10 MU/m2 TIW, up to one complete year of therapy
Trial: 3011048
Drug: Intravenous trimazosin
RxNorm normalized name: trimazosin
DrugBank: Trimazosin (DB09206)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous trimazosin (100 mg)
Trial: 3011048
Drug: Oral trimazosin
RxNorm normalized name: trimazosin
DrugBank: Trimazosin (DB09206)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral trimazosin (200 mg)
Trial: 27733571
Drug: SC IFN‐β‐1a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SC IFN‐β‐1a 44 μg
Trial: 24959193
Drug: Shen-Zhi-Ling oral
RxNorm normalized name: fu ling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shen-Zhi-Ling oral liquid (SZL)
Trial: 22399518
Drug: Mifepristone (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifepristone (600 mg daily for 6 weeks)
Trial: 20726258
Drug: 1 dose
RxNorm normalized name: Ribose 3 GM/1 DOSE Oral Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 dose booster of HepB
Trial: 20726258
Drug: 3 dose
RxNorm normalized name: Hep A, ped/adol, 3 dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 dose booster of HepB
Trial: 20726258
Drug: 4 different
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 different types of HepB (5 microg HepB-Y, 10 microg HepB-Y, 10 microg HepB-CHO, 10 microg HepB-HY) after 3 doses revaccination
Trial: 17681993
Drug: Active treatments
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatments for smoking cessation (specific treatments not detailed)
Trial: 17849193
Drug: New tests
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New tests of the same four predictor domains administered to N=500 late kindergartners through third graders
Trial: 8542861
Drug: nalbuphine mixed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nalbuphine mixed with lignocaine (2 mg mL‐1)
Trial: 8542861
Drug: diluted nalbuphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: diluted nalbuphine (2 mg mL‐1)
Trial: 1930343
Drug: Midazolam (7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (7.5 mg)
Trial: 6885176
Drug: Erythromycin lactobionate
RxNorm normalized name: Erythromycin Lactobionate
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Erythromycin lactobionate (1 g in 0.9% NaCl) infused in 120 ml
Trial: 6885176
Drug: Erythromycin lactobionate
RxNorm normalized name: Erythromycin Lactobionate
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Erythromycin lactobionate (1 g in 0.9% NaCl) infused in 250 ml
Trial: 6885176
Drug: Placebo (0.9%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (0.9% NaCl) infused in 120 ml
Trial: 6885176
Drug: Placebo (0.9%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (0.9% NaCl) infused in 250 ml
Trial: 30091666
Drug: Losartan (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan (100 mg/day) with resistance training
Trial: 30091666
Drug: Losartan (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan (100 mg/day) without resistance training
Trial: 22395762
Drug: Multicomponent psychological
RxNorm normalized name: meningococcus B, multicomponent vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multicomponent psychological intervention (milieu therapy interventions and music therapy) for 6 months
Trial: 22395762
Drug: Standard occupational
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard occupational therapy